Search - tctmd.com

Displaying 1 - 20 of 77

Sort: Relevancy | Date

News Daily News

Year in Review: Top Prevention Stories of 2025

Michael O'Riordan

December 24, 2025

News Daily News

ACC: It’s Time for Clinicians to Address Inflammation in CVD

Caitlin E. Cox

October 03, 2025

News Daily News

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Michael O'Riordan

July 14, 2025

News Daily News

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Michael O'Riordan

June 04, 2025

News Daily News

REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF

Michael O'Riordan

March 11, 2025

News Daily News

Lp(a) Levels, Still Mostly Genetic, Sometimes Vary Over a Lifetime

Michael O'Riordan

October 14, 2024

News Daily News

CMS Announces Negotiated Medicare Prices for First 10 Drugs

Yael L. Maxwell

August 16, 2024

News Daily News

Sudden Deaths After Acute MI Have Dropped, but Early Weeks Remain Risky

Yael L. Maxwell

August 08, 2024

News Daily News

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Michael O'Riordan

April 17, 2024

News Conference News ACC 2024

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

Todd Neale

March 27, 2024

News Daily News

High-Risk ‘Clues’ Add Heft to Calcium Scores in Primary Prevention

Michael O'Riordan

February 29, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for December 2023

Caitlin E. Cox

December 28, 2023

News Daily News

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Michael O'Riordan

December 06, 2023

News Conference News AHA 2023

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

Shelley Wood

November 13, 2023

News Conference News AHA 2023

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

Shelley Wood

November 11, 2023

News Conference News ESC 2023

ORION-8: Safe and Durable Longer-Term LDL-Lowering With Inclisiran

Michael O'Riordan

September 01, 2023

News Daily News

First Drugs Chosen for Medicare Negotiations Hit Close to Home for Cardiologists

L.A. McKeown

August 31, 2023

News Daily News

Acute MI Patients Without Standard CVD Risk Factors at Higher Risk of Death

Michael O'Riordan

July 07, 2023

News Daily News

LDL Control Remains Poor in CAD Patients: NHANES

Michael O'Riordan

July 05, 2023

News Daily News

Oxidized Phospholipids and Lp(a) Strongly Associated With MACE: CASABLANCA

Michael O'Riordan

May 03, 2023

Advertisement

Year in Review: Top Prevention Stories of 2025

ACC: It’s Time for Clinicians to Address Inflammation in CVD

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF

Lp(a) Levels, Still Mostly Genetic, Sometimes Vary Over a Lifetime

CMS Announces Negotiated Medicare Prices for First 10 Drugs

Sudden Deaths After Acute MI Have Dropped, but Early Weeks Remain Risky

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

High-Risk ‘Clues’ Add Heft to Calcium Scores in Primary Prevention

TCTMD’s Top 10 Most Popular Stories for December 2023

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

ORION-8: Safe and Durable Longer-Term LDL-Lowering With Inclisiran

First Drugs Chosen for Medicare Negotiations Hit Close to Home for Cardiologists

Acute MI Patients Without Standard CVD Risk Factors at Higher Risk of Death

LDL Control Remains Poor in CAD Patients: NHANES

Oxidized Phospholipids and Lp(a) Strongly Associated With MACE: CASABLANCA

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content